April 2006
Worldwide Biotech;Apr2006, Vol. 18 Issue 4, p6
Trade Publication
Reports on the supply contract entered into by Chiron Corp. with the British government for pre-pandemic influenza vaccine for a stockpile based on the H5N1 avian influenza virus strain. Information on the stockpile vaccine; Terms of the contract; Background on the MF59 adjuvant.


Related Articles

  • Manufacturer Will Not Ship Influenza Vaccine as Expected. Ressel, Genevieve // American Family Physician;11/1/2004, Vol. 70 Issue 9, p1625 

    Reports on the announcement of Chiron Corp. that it will not ship its influenza vaccine Fluvirin, after British health authorities suspended the manufacturing license for the company's facility in Liverpool, England. Number of doses of the vaccine that Chiron is anticipating to send in the...

  • Chiron: rising from the ashes.  // PharmaWatch: Biotechnology;Mar2006, Vol. 5 Issue 3, p20 

    The article reports on the financial performance of Chiron for the fourth quarter of 2005. Most of the sales and profits of the company were driven by the recommencement of Fluvirin sales. The results increased the company's share price. The confidence of the company has been restored after its...

  • Chiron Will Not Deliver Flu Vaccine.  // Chemical Market Reporter;10/11/2004, Vol. 266 Issue 12, p2 

    Reports the decision by Chiron Corp. that it would not deliver any of its Fluviron vaccine to the U.S. market for the 2004-2005 flu season after the shutdown of the product's production at the its British facility. Reduction in flu vaccine supply; First sign of a problem at the facility; Impact...

  • Weathering the Influenza Vaccine Crisis. Treanor, John // New England Journal of Medicine;11/11/2004, Vol. 351 Issue 20, p2037 

    Reports on the handling of a shortage of influenza vaccines in the United States. Contamination of vaccines supplied by the Chiron Corporation, which caused the company to recall their supplies from the market; Availability of only half the number of vaccines needed in the U.S.; Details of...

  • Warning on flu vaccine supplies.  // Pulse;6/18/2005, Vol. 65 Issue 24, p4 

    Reports that global biopharmaceutical firm Chiron Corp. has warned that it would be unable to meet its production targets in 2005, raising concern on possible shortage of flu vaccine in Great Britain.

  • US lacks back-up for flu vaccine shortfall. Pearson, Helen // Nature;10/14/2004, Vol. 431 Issue 7010, p726 

    Reports that public health officials in the United States lack alternative sources of influenza vaccine. British regulators' suspension of the production of flue vaccine at the California-based Chiron Corp.'s facility in Liverpool, England; Outcomes of an emergency hearing of the government...

  • Vaccine Manufacturer Expecting Delays in Distribution of Fluvirin. Ressel, Genevieve // American Family Physician;10/15/2004, Vol. 70 Issue 8, p1433 

    Reports that Chiron Corp., the manufacturer of the influenza virus vaccine Fluvirin, are expecting delays in distribution of the vaccine. Reason behind the delay; Estimated schedule of shipping of the vaccine.

  • 'Vaccine shortage averted'  // Pulse;7/23/2005, Vol. 65 Issue 29, p7 

    Reports that Chiron Corp. has reassured general practitioners (GP) that it will be able to fulfill influenza vaccine orders in Great Britain. Fear of British GP after quality control problems in a vaccine plant in Germany; Mitigation of the impact of shortages of Begrivac; Reallocation of other...

  • Northern Ireland GPs struggle with shortage of flu vaccines. Russell, Vivienne // Public Finance;10/8/2004, p13 

    Reports that general practitioners in Northern Ireland have cancelled their flu immunization clinics after supplies were affected by the suspension of a major supplier Chiron Corp. Reason behind the suspension of Chiron; Instruction for practices to prioritize patients most at risk; Reaction of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics